Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia.

Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, Iacovelli L, Matrisciano F, Fazio F, Caraci F, Copani A, Battaglia G, Bruno V.

Front Psychiatry. 2019 Feb 14;10:49. doi: 10.3389/fpsyt.2019.00049. eCollection 2019. Review.

2.

In Vivo Non-radioactive Assessment of mGlu5 Receptor-Activated Polyphosphoinositide Hydrolysis in Response to Systemic Administration of a Positive Allosteric Modulator.

Zuena AR, Iacovelli L, Orlando R, Di Menna L, Casolini P, Alemà GS, Di Cicco G, Battaglia G, Nicoletti F.

Front Pharmacol. 2018 Jul 31;9:804. doi: 10.3389/fphar.2018.00804. eCollection 2018.

3.

Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria.

Nardecchia F, Orlando R, Iacovelli L, Colamartino M, Fiori E, Leuzzi V, Piccinin S, Nistico R, Puglisi-Allegra S, Di Menna L, Battaglia G, Nicoletti F, Pascucci T.

Front Neurosci. 2018 Mar 16;12:154. doi: 10.3389/fnins.2018.00154. eCollection 2018.

4.

Targeting metabotropic glutamate receptors in the treatment of primary brain tumors.

Iacovelli L, Orlando R, Rossi A, Spinsanti P, Melchiorri D, Nicoletti F.

Curr Opin Pharmacol. 2018 Feb;38:59-64. doi: 10.1016/j.coph.2018.02.005. Epub 2018 Mar 8. Review.

PMID:
29525720
5.

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.

Di Menna L, Joffe ME, Iacovelli L, Orlando R, Lindsley CW, Mairesse J, Gressèns P, Cannella M, Caraci F, Copani A, Bruno V, Battaglia G, Conn PJ, Nicoletti F.

Neuropharmacology. 2018 Jan;128:301-313. doi: 10.1016/j.neuropharm.2017.10.026. Epub 2017 Oct 25.

6.

Paradoxical sleep deprivation in rats causes a selective reduction in the expression of type-2 metabotropic glutamate receptors in the hippocampus.

Panaccione I, Iacovelli L, di Nuzzo L, Nardecchia F, Mauro G, Janiri D, De Blasi A, Sani G, Nicoletti F, Orlando R.

Pharmacol Res. 2017 Mar;117:46-53. doi: 10.1016/j.phrs.2016.11.029. Epub 2016 Nov 23.

PMID:
27890550
7.

Type-7 metabotropic glutamate receptors negatively regulate α1-adrenergic receptor signalling.

Iacovelli L, Di Menna L, Peterlik D, Stangl C, Orlando R, Molinaro G, De Blasi A, Bruno V, Battaglia G, Flor PJ, Uschold-Schmidt N, Nicoletti F.

Neuropharmacology. 2017 Feb;113(Pt A):343-353. doi: 10.1016/j.neuropharm.2016.10.018. Epub 2016 Oct 18.

PMID:
27769854
8.

Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors.

Fazio F, Lionetto L, Curto M, Iacovelli L, Copeland CS, Neale SA, Bruno V, Battaglia G, Salt TE, Nicoletti F.

Neuropharmacology. 2017 Jan;112(Pt B):365-372. doi: 10.1016/j.neuropharm.2016.06.020. Epub 2016 Jun 21. Review.

PMID:
27342123
9.

Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits.

Ignoffo R, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA.

J Oncol Pract. 2016 Apr;12(4):e359-68. doi: 10.1200/JOP.2015.008490. Epub 2016 Mar 22.

PMID:
27006358
10.

BDNF rs6265 methylation and genotype interact on risk for schizophrenia.

Ursini G, Cavalleri T, Fazio L, Angrisano T, Iacovelli L, Porcelli A, Maddalena G, Punzi G, Mancini M, Gelao B, Romano R, Masellis R, Calabrese F, Rampino A, Taurisano P, Di Giorgio A, Keller S, Tarantini L, Sinibaldi L, Quarto T, Popolizio T, Caforio G, Blasi G, Riva MA, De Blasi A, Chiariotti L, Bollati V, Bertolino A.

Epigenetics. 2016;11(1):11-23. doi: 10.1080/15592294.2015.1117736. Epub 2016 Feb 18.

11.

Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia.

Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, Ulivieri M, Napoletano F, Capi M, Corigliano V, Scaccianoce S, Caruso A, Miele J, De Fusco A, Di Menna L, Comparelli A, De Carolis A, Gradini R, Nisticò R, De Blasi A, Girardi P, Bruno V, Battaglia G, Nicoletti F, Simmaco M.

Sci Rep. 2015 Dec 8;5:17799. doi: 10.1038/srep17799.

12.

Selective regulation of recombinantly expressed mGlu7 metabotropic glutamate receptors by G protein-coupled receptor kinases and arrestins.

Iacovelli L, Felicioni M, Nisticò R, Nicoletti F, De Blasi A.

Neuropharmacology. 2014 Feb;77:303-12. doi: 10.1016/j.neuropharm.2013.10.013. Epub 2013 Oct 19.

PMID:
24148810
13.

Molecular mechanisms that desensitize metabotropic glutamate receptor signaling: an overview.

Iacovelli L, Nicoletti F, De Blasi A.

Neuropharmacology. 2013 Mar;66:24-30. doi: 10.1016/j.neuropharm.2012.05.005. Epub 2012 May 29. Review.

PMID:
22659473
14.

Estrogen receptors and type 1 metabotropic glutamate receptors are interdependent in protecting cortical neurons against β-amyloid toxicity.

Spampinato SF, Molinaro G, Merlo S, Iacovelli L, Caraci F, Battaglia G, Nicoletti F, Bruno V, Sortino MA.

Mol Pharmacol. 2012 Jan;81(1):12-20. doi: 10.1124/mol.111.074021. Epub 2011 Oct 7.

PMID:
21984253
15.

Viral infection for GPCR expression in eukaryotic cells.

Porcellini A, Iacovelli L, De Blasi A.

Methods Mol Biol. 2011;746:39-51. doi: 10.1007/978-1-61779-126-0_3.

PMID:
21607851
16.

Stress-related methylation of the catechol-O-methyltransferase Val 158 allele predicts human prefrontal cognition and activity.

Ursini G, Bollati V, Fazio L, Porcelli A, Iacovelli L, Catalani A, Sinibaldi L, Gelao B, Romano R, Rampino A, Taurisano P, Mancini M, Di Giorgio A, Popolizio T, Baccarelli A, De Blasi A, Blasi G, Bertolino A.

J Neurosci. 2011 May 4;31(18):6692-8. doi: 10.1523/JNEUROSCI.6631-10.2011.

17.

Role of oncology clinical pharmacists in light of the oncology workforce study.

Sessions JK, Valgus J, Barbour SY, Iacovelli L.

J Oncol Pract. 2010 Sep;6(5):270-2. doi: 10.1200/JOP.000037.

18.

DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, Fazio L, Gelao B, Di Giorgio A, Iacovelli L, Sinibaldi L, Popolizio T, Usiello A, Bertolino A.

Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1158-63. doi: 10.1073/pnas.1013535108. Epub 2010 Dec 27.

19.

Blood pressure control in patients receiving bevacizumab in an outpatient cancer center.

Bottiglieri S, Muluneh B, Sutphin S, Iacovelli L, Adams V.

J Oncol Pharm Pract. 2011 Dec;17(4):333-8. doi: 10.1177/1078155210382150. Epub 2010 Sep 3.

PMID:
20817652
20.
21.

Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization.

Iacovelli L, Molinaro G, Battaglia G, Motolese M, Di Menna L, Alfiero M, Blahos J, Matrisciano F, Corsi M, Corti C, Bruno V, De Blasi A, Nicoletti F.

Mol Pharmacol. 2009 Apr;75(4):991-1003. doi: 10.1124/mol.108.052316. Epub 2009 Jan 22.

PMID:
19164443
22.

Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.

Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.

Pharmacotherapy. 2008 May;28(5 Pt 2):1S-15S. doi: 10.1592/phco.28.5supp.1S.

PMID:
18447704
23.

Involvement of dopamine receptors and beta-arrestin in metamphetamine-induced inclusions formation in PC12 cells.

Fornai F, Lenzi P, Capobianco L, Iacovelli L, Scarselli P, Lazzeri G, De Blasi A.

J Neurochem. 2008 Jun;105(5):1939-47. doi: 10.1111/j.1471-4159.2008.05284.x. Epub 2008 Feb 7.

24.

Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.

Iacovelli L.

Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):31-3.

25.

Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis.

Matrisciano F, Zusso M, Panaccione I, Turriziani B, Caruso A, Iacovelli L, Noviello L, Togna G, Melchiorri D, Debetto P, Tatarelli R, Battaglia G, Nicoletti F, Giusti P, Girardi P.

Neuropharmacology. 2008 Feb;54(2):428-37. Epub 2007 Nov 7.

PMID:
18082849
26.

Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease.

Castri P, Iacovelli L, De Blasi A, Giubilei F, Moretti A, Tari Capone F, Nicoletti F, Orzi F.

Eur J Neurosci. 2007 Nov;26(9):2469-72.

PMID:
17986027
27.

Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication?

Matrisciano F, Panaccione I, Zusso M, Giusti P, Tatarelli R, Iacovelli L, Mathé AA, Gruber SH, Nicoletti F, Girardi P.

Mol Psychiatry. 2007 Aug;12(8):704-6. No abstract available.

PMID:
17653204
28.

Metabotropic glutamate receptors: beyond the regulation of synaptic transmission.

Nicoletti F, Battaglia G, Storto M, Ngomba RT, Iacovelli L, Arcella A, Gradini R, Sale P, Rampello L, De Vita T, Di Marco R, Melchiorri D, Bruno V.

Psychoneuroendocrinology. 2007 Aug;32 Suppl 1:S40-5. Epub 2007 Jul 24. Review.

PMID:
17651904
29.

Metabotropic glutamate receptors: new targets for the control of tumor growth?

Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D.

Trends Pharmacol Sci. 2007 May;28(5):206-13. Epub 2007 Apr 11.

PMID:
17433452
30.

Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas.

Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P, Caruso A, De Smaele E, Saran A, Gulino A, D'Onofrio M, Giangaspero F, Nicoletti F.

J Neurosci. 2006 Aug 9;26(32):8388-97.

31.

Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells.

Caruso A, Motolese M, Iacovelli L, Caraci F, Copani A, Nicoletti F, Terstappen GC, Gaviraghi G, Caricasole A.

J Neurochem. 2006 Jul;98(2):364-71.

32.

The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders.

Iacovelli L, Fulceri F, De Blasi A, Nicoletti F, Ruggieri S, Fornai F.

Exp Neurol. 2006 Sep;201(1):24-31. Epub 2006 May 5. Review.

PMID:
16678160
33.

Endogenous activation of metabotropic glutamate receptors supports the proliferation and survival of neural progenitor cells.

Di Giorgi-Gerevini V, Melchiorri D, Battaglia G, Ricci-Vitiani L, Ciceroni C, Busceti CL, Biagioni F, Iacovelli L, Canudas AM, Parati E, De Maria R, Nicoletti F.

Cell Death Differ. 2005 Aug;12(8):1124-33.

34.

PHCCC, a specific enhancer of type 4 metabotropic glutamate receptors, reduces proliferation and promotes differentiation of cerebellar granule cell neuroprecursors.

Canudas AM, Di Giorgi-Gerevini V, Iacovelli L, Nano G, D'Onofrio M, Arcella A, Giangaspero F, Busceti C, Ricci-Vitiani L, Battaglia G, Nicoletti F, Melchiorri D.

J Neurosci. 2004 Nov 17;24(46):10343-52.

35.

Analysis of differential modulatory activities of GRK2 and GRK4 on Galphaq-coupled receptor signaling.

Picascia A, Capobianco L, Iacovelli L, De Blasi A.

Methods Enzymol. 2004;390:337-53.

PMID:
15488187
36.

Activation of Fas receptor is required for the increased formation of the disialoganglioside GD3 in cultured cerebellar granule cells committed to apoptotic death.

Castiglione M, Spinsanti P, Iacovelli L, Lenti L, Martini F, Gradini R, Di Giorgi Gerevini V, Caricasole A, Caruso A, De Maria R, Nicoletti F, Melchiorri D.

Neuroscience. 2004;126(4):889-98.

PMID:
15207324
37.

Regulation of mGlu4 metabotropic glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2).

Iacovelli L, Capobianco L, Iula M, Di Giorgi Gerevini V, Picascia A, Blahos J, Melchiorri D, Nicoletti F, De Blasi A.

Mol Pharmacol. 2004 May;65(5):1103-10.

PMID:
15102938
38.

Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium.

Granata F, Potenza RL, Fiori A, Strom R, Caronti B, Molinari P, Donsante S, Citro G, Iacovelli L, De Blasi A, Ngomba RT, Palladini G, Passarelli F.

Eur J Pharmacol. 2003 Dec 15;482(1-3):17-23.

PMID:
14660000
39.

Presence of beta-arrestin in cellular inclusions in metamphetamine-treated PC12 cells.

De Blasi A, Capobianco L, Iacovelli L, Lenzi P, Ferrucci M, Lazzeri G, Fornai F, Picascia A.

Neurol Sci. 2003 Oct;24(3):164-5.

PMID:
14598068
40.

Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins.

Caricasole A, Ferraro T, Iacovelli L, Barletta E, Caruso A, Melchiorri D, Terstappen GC, Nicoletti F.

J Biol Chem. 2003 Sep 26;278(39):37024-31. Epub 2003 Jul 11.

41.

The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease?

Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, Nicoletti F.

Trends Pharmacol Sci. 2003 May;24(5):233-8. Review.

PMID:
12767722
42.

Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a.

Giorelli M, De Blasi A, Defazio G, Avolio C, Iacovelli L, Livrea P, Trojano M.

Cell Commun Adhes. 2002 Sep-Dec;9(5-6):259-72.

PMID:
12745437
43.

Role of G protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases.

Iacovelli L, Salvatore L, Capobianco L, Picascia A, Barletta E, Storto M, Mariggiò S, Sallese M, Porcellini A, Nicoletti F, De Blasi A.

J Biol Chem. 2003 Apr 4;278(14):12433-42. Epub 2003 Jan 7.

44.

Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways.

Iacovelli L, Bruno V, Salvatore L, Melchiorri D, Gradini R, Caricasole A, Barletta E, De Blasi A, Nicoletti F.

J Neurochem. 2002 Jul;82(2):216-23.

45.

Regulation of lysophosphatidic acid receptor-stimulated response by G-protein-coupled receptor kinase-2 and beta-arrestin1 in FRTL-5 rat thyroid cells.

Iacovelli L, Capobianco L, D'Ancona GM, Picascia A, De Blasi A.

J Endocrinol. 2002 Jul;174(1):103-10.

PMID:
12098668
46.

Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes.

Giorelli M, Livrea P, Defazio G, Iacovelli L, Capobianco L, Picascia A, Sallese M, Martino D, Aniello MS, Trojano M, De Blasi A.

Cell Signal. 2002 Aug;14(8):673-8.

PMID:
12020767
47.

Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism.

Iacovelli L, Capobianco L, Salvatore L, Sallese M, D'Ancona GM, De Blasi A.

Mol Pharmacol. 2001 Nov;60(5):924-33.

PMID:
11641420
48.

Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins.

Sallese M, Iacovelli L, Cumashi A, Capobianco L, Cuomo L, De Blasi A.

Biochim Biophys Acta. 2000 Dec 20;1498(2-3):112-21. Review.

49.

Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated galphaq.

Sallese M, Mariggiò S, D'Urbano E, Iacovelli L, De Blasi A.

Mol Pharmacol. 2000 Apr;57(4):826-31.

PMID:
10727532
50.

Involvement of G protein-coupled receptor kinases and arrestins in desensitization to follicle-stimulating hormone action.

Troispoux C, Guillou F, Elalouf JM, Firsov D, Iacovelli L, De Blasi A, Combarnous Y, Reiter E.

Mol Endocrinol. 1999 Sep;13(9):1599-614.

PMID:
10478849

Supplemental Content

Loading ...
Support Center